SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant 10.2% Stake in Foghorn Therapeutics

FMR LLC and Abigail P. Johnson have reported a continued beneficial ownership of 10.2% of Foghorn Therapeutics Inc.'s common stock as of December 31, 2024, through a Schedule 13G Amendment No. 5 filing.

Summary

• FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 5,689,719 shares of Foghorn Therapeutics Inc. common stock.
• This aggregate amount represents 10.2% of the company's outstanding common stock as of December 31, 2024.
• FMR LLC holds sole voting power over 5,688,325 shares and sole dispositive power over 5,689,719 shares.
• Abigail P. Johnson holds sole dispositive power over 5,689,719 shares, with no sole or shared voting power.
• The shares are stated to be acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The filing is an Amendment No. 5, indicating an update to a previously reported significant stake.

Sentiment

Score: 6

Explanation: The document indicates a continued significant stake by a major institutional investor, which is generally a positive signal of confidence, though it is a routine disclosure and does not provide new operational or financial insights.

Positives

• A major institutional investor, FMR LLC, and its CEO, Abigail P. Johnson, maintain a significant 10.2% stake in Foghorn Therapeutics Inc., which can be interpreted as a continued vote of confidence in the company.
• The holding is for investment purposes in the ordinary course of business, suggesting a passive, long-term investment perspective rather than an activist intent.

Risks

• The document, being a beneficial ownership report, does not detail specific operational or financial risks related to Foghorn Therapeutics Inc.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a routine disclosure of a significant passive ownership stake by a major asset manager in a biotechnology company. It does not provide specific insights into Foghorn Therapeutics' operational performance or broader industry trends, but rather reflects an investment decision by FMR LLC within the broader investment landscape.

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor may be viewed positively, signaling confidence in the company.

Key Dates

Keywords

Foghorn Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals